More Patient Empowerment = More Successful Clinical Studies

USA - English

• USA - Français
• USA - Deutsch

NEWTOWN, Pa., Sept. 16, 2015 /PRNewswire/ -- Optimal Strategix Group (OSG) announced today that the company's CAVII™ app is ready for download in the Apple App Store. CAVII™ is the world's first iOS-based clinical study matching and analytics platform.  Ushering in a new era of patient engagement, CAVII^TM's aim is to revolutionize clinical studies through the use of analytics for superior patient matching.  Through CAVII^TM, clinical studies become more cost-effective, efficient, and ultimately more engaging and insightful for patients and clinicians.

Commenting on the launch, Giri Iyer, OSG's EVP of Analytics stated, "There's a simple truth about global healthcare:  all of us will be patients in the future, and hopefully we'll enjoy more and more advanced solutions.  However, studies show that an average clinical studies costs upwards of $2.5B dollars, and barely 10% of the clinical studies finish on time.  50% of patients in the US simply don't know about clinical studies or how to sign up for one, leading to a massive problem with proper patient recruitment.   Our mission with CAVII is to get patients worldwide involved in clinical studies, using analytics and a big data platform that OSG has developed.  CAVII allows users to import their health data from thousands of top hospitals and medical facilities in the US (an estimated 150 million electronic medical records) thanks to our partner, HumanAPI and their tremendous expertise."

Ashvanni Srivastava, Executive Vice President of OSG's Healthcare Practice, believes that CAVII will help ring in a new era of cost-effective patient controlled healthcare.  Mr. Srivastava, stated "Given the enormous expense involved with clinical studies, a 1% improvement in the current bureaucracy-heavy studies process will save the average Pharmaceutical Company $20-30M a year.  CAVII will put tools in the hands of patients so that they can manage their own studies journey, delivering a beneficial and cost-effective result for patients, clinicians, and pharma companies."

Dr. R. Sukumar, OSG's Founder and CEO regards CAVII^TM as a natural extension of OSG's core strengths, remarking that "We see the use of analytics in CAVII™ as a natural extension of our current business.  Over the last decade, OSG has done over 600 studies with Pharma and Med Devices for industry-leading companies such as Johnson & Johnson, Medtronic/Covidien and BD (formerly Becton Dickinson).  We've helped with all aspects of clinical research and drug or device commercialization studies, ranging from patient/clinician behavioral analytics, patient segmentation, disease segmentation, and target product profiles. CAVII^TM gives pharmaceutical companies the ability to complete clinical studies faster by recruiting and engaging patients effectively, and it uncovers deep, unique, and actionable insights about human behavior."

OSG welcomes interest and inquiries about CAVII^TM, and OSG can provide a detailed product demo for potential partners and industry professionals.  To inquire about a demo session, please contact the CAVII^TM Demo Team:
[email protected]

For general questions or to inquire about partnership opportunities, please contact the CAVII^TM Marketing team:
[email protected]

Find CAVII^TM On Social Media:
https://twitter.com/CAVIIStudies 
https://www.facebook.com/CAVIIClinicalStudies

About Optimal Strategix Group (OSG)
OSG helps clients grow their business by becoming more customer-centric through insights, analytics, advisement and technology.  OSG serves global Fortune 1000 companies in the consumer goods, business to business, life sciences, and healthcare sectors. Headquartered in Newtown, PA, OSG currently has offices in New York City, San Francisco, Bangalore, Manchester (U.K.), and Madrid.

CONTACT: Cory Pierce, [email protected]

Logo - http://photos.prnewswire.com/prnh/20140515/88071

SOURCE Optimal Strategix Group, Inc.

Related Links

www.optimalstrategix.com